Karyopharm Absorbs Selinexor AML Blow, Focuses On Other Cancers

Upcoming Phase II in diffuse large B-cell lymphoma offers opportunity for a rebound after single agent selinexor disappoints in SOPRA study of acute myeloid leukemia.